Characterization of hepatic and intestinal glucuronidation of magnolol: Application of the relative activity factor approach to decipher the contributions of multiple UDP-glucuronosyltransferase isoforms

Drug Metabolism and Disposition

Volumn 40, Issue 3, 2012, Pages 529-538

  Zhu, Liangliang ^a,b   Ge, Guangbo ^a   Zhang, Hongbo ^c   Liu, Huixin ^a   He, Guiyuan ^a,b   Liang, Sicheng ^a   Zhang, Yanyan ^a   Fang, Zhongze ^a   Dong, Peipei ^a   Finel, Moshe ^c   Yang, Ling ^a  

^a DALIAN INSTITUTE OF CHEMICAL PHYSICS   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A10; GLUCURONOSYLTRANSFERASE 1A3; GLUCURONOSYLTRANSFERASE 1A7; GLUCURONOSYLTRANSFERASE 1A8; GLUCURONOSYLTRANSFERASE 1A9; GLUCURONOSYLTRANSFERASE 2B7; MAGNOLOL;

ARTICLE; CATALYSIS; CONTROLLED STUDY; GLUCURONIDATION; HUMAN; INHIBITION KINETICS; INTESTINE MICROSOME; LIVER MICROSOME; MICROSOME; PRIORITY JOURNAL;

BIPHENYL COMPOUNDS; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; INTESTINES; KINETICS; LIGNANS; LIVER; MICROSOMES; MICROSOMES, LIVER; PROTEIN ISOFORMS; RECOMBINANT PROTEINS;

EID: 84863180549     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.042192     Document Type: Article

References (32)

1. Court MH, Krishnaswamy S, Hao Q, Duan SX, Patten CJ, Von Moltke LL, and Greenblatt DJ (2003) Evaluation of 3′-azido-3′-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. Drug Metab Dispos 31:1125-1133. (Pubitemid 37048284)
2. Crespi CL and Miller VP (1999) The use of heterologously expressed drug metabolizing enzymes - state of the art and prospects for the future. Pharmacol Ther 84:121-131. (Pubitemid 29488547)
3. Fakhrudin N, Ladurner A, Atanasov AG, Heiss EH, Baumgartner L, Markt P, Schuster D, Ellmerer EP, Wolber G, Rollinger JM, et al. (2010) Computer-aided discovery, validation, and mechanistic characterization of novel neolignan activators of peroxisome proliferator-activated receptor γ. Mol Pharmacol 77:559-566.
4. Greenberg M, Urnezis P, and Tian M (2007) Compressed mints and chewing gum containing magnolia bark extract are effective against bacteria responsible for oral malodor. J Agric Food Chem 55:9465-9469. (Pubitemid 350205298)
5. Hattori M, Endo Y, Takebe S, Kobashi K, Fukasaku N, and Namba T (1986) Metabolism of magnolol from Magnoliae cortex. II. Absorption, metabolism and excretion of [ring-14C]magnolol in rats. Chem Pharm Bull 34:158-167. (Pubitemid 16135903)
6. Homma M, Oka K, Kobayashi H, Niitsuma T, Yamamoto S, Itoh H, and Takahashi N (1993) Liquid chromatographic determination of magnolol in urine collected from volunteers after a single dose of saiboku-to, an oriental herbal medicine for bronchial asthma. J Pharm Pharmacol 45:839-841.
7. Itäaho K, Court MH, Uutela P, Kostiainen R, Radominska-Pandya A, and Finel M (2009) Dopamine is a low-affinity and high-specificity substrate for the human UDP-glucuronosyltransferase 1A10. Drug Metab Dispos 37:768-775.
8. Kurkela M, Patana AS, Mackenzie PI, Court MH, Tate CG, Hirvonen J, Goldman A, and Finel M (2007) Interactions with other human UDP- glucuronosyltransferases attenuate the consequences of the Y485D mutation on the activity and substrate affinity of UGT1A6. Pharmacogenet Genomics 17:115-126.
9. Kuuranne T, Kurkela M, Thevis M, Schänzer W, Finel M, and Kostiainen R (2003) Glucuronidation of anabolic androgenic steroids by recombinant human UDP-glucuronosyltransferases. Drug Metab Dispos 31:1117-1124. (Pubitemid 37048283)
10. Lee YJ, Lee YM, Lee CK, Jung JK, Han SB, and Hong JT (2011) Therapeutic applications of compounds in the Magnolia family. Pharmacol Ther 130:157-176.
11. Li W, Liu Y, He YQ, Zhang JW, Gao Y, Ge GB, Liu HX, Huo H, Liu HT, Wang LM, et al. (2008) Characterization of triptolide hydroxylation by cytochrome P450 in human and rat liver microsomes. Xenobiotica 38:1551-1565.
12. Liang SC, Ge GB, Liu HX, Shang HT, Wei H, Fang ZZ, Zhu LL, Mao YX, and Yang L (2011) Determination of propofol UDP-glucuronosyltransferase (UGT) activities in hepatic microsomes from different species by UFLC-ESI-MS. J Pharm Biomed Anal 54:236-241.
13. Mackenzie PI, Bock KW, Burchell B, Guillemette C, Ikushiro S, Iyanagi T, Miners JO, Owens IS, and Nebert DW (2005) Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics 15:677-685. (Pubitemid 41345319)
14. Miners JO, Bowalgaha K, Elliot DJ, Baranczewski P, and Knights KM (2011) Characterization of niflumic acid as a selective inhibitor of human liver microsomal UDP-glucuronosyltransferase 1A9: application to the reaction phenotyping of acetaminophen glucuronidation. Drug Metab Dispos 39:644-652.
15. Miners JO, Mackenzie PI, and Knights KM (2010) The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential. Drug Metab Rev 42:196-208.
16. Ohno S and Nakajin S (2009) Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction. Drug Metab Dispos 37:32-40.
17. Rouguieg K, Picard N, Sauvage FL, Gaulier JM, and Marquet P (2010) Contribution of the different UDP-glucuronosyltransferase (UGT) isoforms to buprenorphine and norbuprenorphine metabolism and relationship with the main UGT polymorphisms in a bank of human liver microsomes. Drug Metab Dispos 38:40-45.
18. Sneitz N, Court MH, Zhang XL, Laajanen K, Yee KK, Dalton P, Ding XX, and Finel M (2009) Human UDP-glucuronosyltransferase UGT2A2: cDNA construction, expression, and functional characterization in comparison with UGT2A1 and UGT2A3. Pharmacogenet Genomics 19:923-934.
19. Soars MG, Petullo DM, Eckstein JA, Kasper SC, and Wrighton SA (2004) An assessment of UDP-glucuronosyltransferase induction using primary human hepatocytes. Drug Metab Dispos 32:140-148. (Pubitemid 38112546)
20. Soars MG, Ring BJ, and Wrighton SA (2003) The effect of incubation conditions on the enzyme kinetics of UDP-glucuronosyltransferases. Drug Metab Dispos 31:762-767. (Pubitemid 36617665)
21. Strassburg CP, Kneip S, Topp J, Obermayer-Straub P, Barut A, Tukey RH, and Manns MP (2000) Polymorphic gene regulation and interindividual variation of UDP-glucuronosyltransferase activity in human small intestine. J Biol Chem 275:36164-36171.
22. Strassburg CP, Manns MP, and Tukey RH (1998) Expression of the UDP-glucuronosyltransferase 1A locus in human colon. Identification and characterization of the novel extrahepatic UGT1A8. J Biol Chem 273:8719-8726. (Pubitemid 28176150)
23. Strassburg CP, Strassburg A, Kneip S, Barut A, Tukey RH, Rodeck B, and Manns MP (2002) Developmental aspects of human hepatic drug glucuronidation in young children and adults. Gut 50:259-265. (Pubitemid 34087942)
24. Toide K, Terauchi Y, Fujii T, Yamazaki H, and Kamataki T (2004) Uridine diphosphate sugar-selective conjugation of an aldose reductase inhibitor (AS-3201) by UDP-glucuronosyltransferase 2B subfamily in human liver microsomes. Biochem Pharmacol 67: 1269-1278. (Pubitemid 38315092)
25. Tsai TH, Chou CJ, and Chen CF (1995) Glucuronidation of magnolol assessed using HPLC/ fluorescence. Planta Medica 61:491-492.
26. Uchaipichat V, Mackenzie PI, Elliot DJ, and Miners JO (2006) Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone) "probes" for human UDP-glucuronosyltransferases. Drug Metab Dispos 34:449-456.
27. Uchaipichat V, Mackenzie PI, Guo XH, Gardner-Stephen D, Galetin A, Houston JB, and Miners JO (2004) Human UDP-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. Drug Metab Dispos 32:413-423. (Pubitemid 38420275)
28. Uutela P, Karhu L, Piepponen P, Käenmäki M, Ketola RA, and Kostiainen R (2009) Discovery of dopamine glucuronide in rat and mouse brain microdialysis samples using liquid chromatography tandem mass spectrometry. Anal Chem 81:427-434.
29. Wells PG, Mackenzie PI, Chowdhury JR, Guillemette C, Gregory PA, Ishii Y, Hansen AJ, Kessler FK, Kim PM, Chowdhury NR, et al. (2004) Glucuronidation and the UDP-glucuronosyltransferases in health and disease. Drug Metab Dispos 32:281-290. (Pubitemid 38263885)
30. Zaya MJ, Hines RN, and Stevens JC (2006) Epirubicin glucuronidation and UGT2B7 developmental expression. Drug Metab Dispos 34:2097-2101. (Pubitemid 44837771)
31. Zhang H, Tolonen A, Rousu T, Hirvonen J, and Finel M (2011) Effects of cell differentiation and assay conditions on the UDP-glucuronosyltransferase activity in Caco-2 cells. Drug Metab Dispos 39:456-464.
32. Zhang YY, Liu Y, Zhang JW, Ge GB, Wang LM, Sun J, and Yang L (2009) Characterization of human cytochrome P450 isoforms involved in the metabolism of 7-epi-paclitaxel. Xenobiotica 39:283-292.